Table 1.
Characteristics of patients with microsatellite stable metastatic colorectal cancer
| Characteristics | COH/UCD | MSKCC | ||||||
|---|---|---|---|---|---|---|---|---|
| Total (%)(n = 341) | APC‐WT (n = 86) | APC‐MT (n = 255) | p value | Total (%)(n = 934) | APC‐WT (n = 216) | APC‐MT (n = 718) | p value | |
| Age at diagnosis, median (range), yr | 56 (16–88) | 55 (16–85) | 56 (20–88) | .16 | 53 (13–93) | 53 (13–83) | 53 (22–93) | .25 |
| Gender, n (%) | ||||||||
| Male | 192 (56.3) | 44 (51.2) | 148 (58.0) | 494 (52.9) | 113 (52.3) | 381 (53.1) | ||
| Female | 149 (43.7) | 42 (48.8) | 107 (42.0) | .32 | 440 (47.1) | 103 (47.7) | 337 (46.9) | .88 |
| Site, a n (%) | ||||||||
| Right | 103 (30.7) | 35 (41.7) | 68 (27.0) | 241 (26.1) | 75 (35.5) | 166 (23.3) | ||
| Left | 233 (69.3) | 49 (58.3) | 184 (73.0) | .014 | 681 (73.9) | 136 (64.5) | 545 (76.7) | 6.60 × 10−04 |
| BRAF V600E, n (%) | ||||||||
| Mutated | 22 (6.5) | 20 (23.3) | 2 (0.8) | 49 (5.2) | 31 (14.4) | 18 (2.5) | ||
| Nonmutated | 319 (93.5) | 66 (76.7) | 253 (99.2) | 2.60 × 10−11 | 885 (94.8) | 185 (85.6) | 700 (97.5) | 6.98 × 10−10 |
| KRAS, n (%) | ||||||||
| Mutated | 158 (46.3) | 30 (34.9) | 128 (50.2) | 424 (45.4) | 92 (42.6) | 332 (46.2) | ||
| Nonmutated | 183 (53.7) | 56 (65.1) | 127 (49.8) | .017 | 510 (54.6) | 124 (57.4) | 386 (53.8) | .35 |
| NRAS, n (%) | ||||||||
| Mutated | 15 (4.4) | 3 (3.5) | 12 (4.7) | 38 (4.1) | 1 (.5) | 37 (5.2) | ||
| Nonmutated | 326 (95.6) | 83 (96.5) | 243 (95.3) | .77 | 896 (95.9) | 215 (99.5) | 681 (94.8) | 6.70 × 10−04 |
| TP53, n (%) | ||||||||
| Mutated | 257 (75.4) | 69 (80.2) | 188 (73.7) | 727 (77.8) | 169 (78.2) | 558 (77.7) | ||
| Nonmutated | 84 (24.6) | 17 (19.8) | 67 (26.3) | .25 | 207 (22.2) | 47 (21.8) | 160 (22.3) | .93 |
a
Data not available: 5 cases in the COH/UCD and 12 cases in theMSKCC cohort.
Abbreviations: APC‐MT, APC mutation; APC‐WT, wild‐type APC; COH, City of Hope National Medical Center; UCD, University of California, Davis.